THOUSAND OAKS, Calif.,
March 14, 2017 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) will host a webcast investor meeting at the American
College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17, 2017, at noon ET. Sean E.
Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical
development team and clinical investigators, will participate at
the investor meeting to discuss Amgen's cardiovascular program and
data presented at ACC.17, including the Repatha®
(evolocumab) cardiovascular outcomes study (FOURIER) Phase 3
results.
Live audio of the investor meeting will be simultaneously
broadcast over the internet and will be available to members of the
news media, investors and the general public. The webcast, as with
other selected presentations regarding developments
in Amgen's business given at certain investor and medical
conferences, can be accessed
from Amgen's website, www.amgen.com, under
Investors.
Webcasts of Late-Breaking Clinical Trial
Presentations
Detailed results from the Repatha
cardiovascular outcomes trial (FOURIER) will be featured as a
late-breaking oral presentation at ACC.17 on Friday, March
17 at 9 a.m. ET. A second late-breaking oral
presentation, the Repatha cognitive function trial (EBBINGHAUS),
will be presented at ACC.17 on Saturday, March
18 at 9 a.m. ET.
Live audio and video of these two late-breaking clinical trial
presentations will be webcast over the internet simultaneously with
the presentations and will be available to members of the news
media, investors and the general public. The webcasts can be
accessed from Amgen's website, www.amgen.com, under Investors.
Information regarding presentation times, webcast availability
and webcast links are noted on Amgen's Investor Relations
Events Calendar on Amgen's website, www.amgen.com. The webcasts
will be archived and available for replay for at least 90 days
after the event.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Kristen Neese, 805-313-8267
(media)
Arvind Sood, 805-447-1060
(investors)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-scientific-sessions-300423542.html
SOURCE Amgen